Miller-Dieker syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:531OMIM:247200Q04.3
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Miller-Dieker syndrome (MDS), also known as Miller-Dieker lissencephaly syndrome (MDLS), is a rare genetic disorder characterized by classical lissencephaly (smooth brain) and distinctive facial features. It results from a deletion of genetic material on the short arm of chromosome 17 (17p13.3), which includes the PAFAH1B1 (LIS1) gene and the YWHAE gene. The deletion of LIS1 is primarily responsible for the lissencephaly, while loss of additional genes in the deleted region contributes to the characteristic craniofacial abnormalities and other features. The brain malformation arises from defective neuronal migration during embryonic development, resulting in a smooth or nearly smooth cerebral surface with a thickened cortex and absent or reduced gyri and sulci. The syndrome primarily affects the central nervous system, leading to severe intellectual disability, profound developmental delay, and seizures that typically begin in infancy and are often refractory to treatment. Affected individuals usually have significant hypotonia (low muscle tone) that may progress to spasticity. Characteristic facial features include a prominent forehead, bitemporal hollowing, short nose with upturned nares, a thickened upper lip, and a small jaw (micrognathia). Microcephaly (abnormally small head) is also commonly present. Additional features may include feeding difficulties, failure to thrive, and congenital heart defects in some cases. The prognosis for Miller-Dieker syndrome is poor, with most affected children surviving only into early childhood, though some may live longer with supportive care. There is currently no cure or disease-modifying treatment. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, nutritional support (often requiring gastrostomy tube feeding), physical therapy, and management of respiratory complications. Genetic counseling is important for families, as the deletion may arise de novo or may result from a balanced chromosomal rearrangement in a parent, which carries a significant recurrence risk.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal upper lip morphologyHP:0000177LissencephalyHP:0001339
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Miller-Dieker syndrome.

View clinical trials →

No actively recruiting trials found for Miller-Dieker syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Miller-Dieker syndrome community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Miller-Dieker syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Miller-Dieker syndromeForum →

No community posts yet. Be the first to share your experience with Miller-Dieker syndrome.

Start the conversation →

Latest news about Miller-Dieker syndrome

No recent news articles for Miller-Dieker syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Miller-Dieker syndrome

What is Miller-Dieker syndrome?

Miller-Dieker syndrome (MDS), also known as Miller-Dieker lissencephaly syndrome (MDLS), is a rare genetic disorder characterized by classical lissencephaly (smooth brain) and distinctive facial features. It results from a deletion of genetic material on the short arm of chromosome 17 (17p13.3), which includes the PAFAH1B1 (LIS1) gene and the YWHAE gene. The deletion of LIS1 is primarily responsible for the lissencephaly, while loss of additional genes in the deleted region contributes to the characteristic craniofacial abnormalities and other features. The brain malformation arises from defec

How is Miller-Dieker syndrome inherited?

Miller-Dieker syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Miller-Dieker syndrome typically begin?

Typical onset of Miller-Dieker syndrome is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Miller-Dieker syndrome?

1 specialists and care centers treating Miller-Dieker syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.